Background
==========

Alzheimer's disease (AD) is one of the most common forms of dementia. The clinical manifestations of AD include loss of memory, and behavioral and cognitive disorders \[[@b1-medscimonit-21-1408]\]. The survival time for patients with AD is generally 4 to 6 years after diagnosis. Thus, AD is a major public health concern. However, the etiology and pathogenesis of AD remain unclear. Recently, accumulating evidence shows that genetic factors might be involved in the development of AD \[[@b2-medscimonit-21-1408]\].

Butyrylcholinesterase (BCHE) is a hydrolytic enzyme that can catalyze the hydrolysis of excess acetylcholine neurotransmission in the synaptic space. Darreh-Shori et al. suggested that low cerebrospinal fluid (CSF) levels of BCHE might predict extensive incorporation in neuritic plaques, greater central neurodegeneration, and increased neurotoxicity \[[@b3-medscimonit-21-1408]\]. They also found that BCHE levels correlated with cerebral glucose metabolism, cerebral β-amyloid load, and CSF P-tau \[[@b4-medscimonit-21-1408]\]. Diamant et al. reported an association of the BChE-K variant with impaired interaction with the fibrillogenic beta-amyloid protein \[[@b5-medscimonit-21-1408]\]. Shenhar-Tsarfaty also suggested that this variant could influence metabolic syndrome \[[@b6-medscimonit-21-1408]\].

BCHE K variant is one of the most common polymorphism in the BCHE gene. This is an alanine-to-threonine substitution in the 539 amino acid position (Ala539Thr). This polymorphism is associated with a 30% reduction of serum BCHE activity \[[@b7-medscimonit-21-1408]\]. Many studies have been conducted to evaluate the association between BCHE K variant and AD risk \[[@b8-medscimonit-21-1408]--[@b32-medscimonit-21-1408]\]. However, the results are controversial and inconsistent. Therefore, we performed a meta-analysis to assess the association between BCHE K variant and AD risk.

Material and Methods
====================

Search for studies
------------------

We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. The last retrieval date was October 29, 2014. The following terms and keywords were used: ("Alzheimer's disease" or "Alzheimer disease") and ("Butyrylcholinesterase" or "BCHE"). All relevant studies were retrieved.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: (1) the study should be case-control or a cohort design; and (2) the study should focus on the association between BCHE K variant and AD risk. The exclusion criteria were as follows: (1) animal studies; (2) reviews or abstracts; and (3) duplications.

Data extraction
---------------

According to the inclusion criteria, 2 investigators extracted the data independently. Any discrepancy was adjudicated by the third investigator. The following data was extracted from each study: first author, year, ethnicity, age and sex of patients, sample size, and genotyping results from BCHE and APOE genes.

Statistical analysis
--------------------

The odds ratio (OR) and its 95% confidence interval (95% CI) were used to estimate the strength of the association between BCHE K variant and AD risk. A recessive model (KK *vs.* WW+WK) was applied. We estimated the heterogeneity by using the chi-square-based Q-test, which was considered significant at P\<0.10. A fixed-effects model was used in the absence of heterogeneity; otherwise, a random-effects model was used. Subgroup analyses were performed based on ethnicity, *APOE* ɛ4 status, and the age at AD onset. We conducted sensitivity analysis by excluding every study individually and recalculating the OR and 95% CI. Potential publication bias was estimated using Egger's linear regression test and the funnel plot. All statistical analyses were conducted using STATA software version 11.0 (Stata Corporation, College Station, TX). All P values were 2-sided, with a significance level of 0.05.

Results
=======

Study characteristics
---------------------

A total of 25 eligible case-control studies (3850 cases and 3947 controls) met the inclusion criteria \[[@b8-medscimonit-21-1408]--[@b32-medscimonit-21-1408]\]. Among these 25 case-control studies, 5 studies focused on Asians and 20 focused on Caucasians. The main characteristics of the included studies investigating the association of BCHE K variant and AD risk are presented in [Table 1](#t1-medscimonit-21-1408){ref-type="table"}.

Association between BCHE K variant and AD risk
----------------------------------------------

We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03--1.39; *P*=0.02; [Figure 1](#f1-medscimonit-21-1408){ref-type="fig"}). In the stratified analysis by ethnicity ([Table 2](#t2-medscimonit-21-1408){ref-type="table"}), we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02--1.72; *P*=0.04), but no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95--1.37; *P*=0.16). When stratified by age at AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05--1.97; *P*=0.02). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89--1.51; *P*=0.27).

Compared with non-*APOE* ɛ4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91--1.35; *P*=0.30). However, *APOE* ɛ4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95%CI 1.75--4.51; P=0.0001) and BCHE K carriers (OR=3.31; 95% CI 1.82--6.02; P=0.0001). Results are listed in [Table 3](#t3-medscimonit-21-1408){ref-type="table"}.

Sensitivity analysis and publication bias
-----------------------------------------

In the sensitivity analysis, the impact of each study on the pooled OR was checked by repeating the meta-analysis when omitting each study. This sensitivity analysis validated the stability of the results from this meta-analysis ([Figure 2](#f2-medscimonit-21-1408){ref-type="fig"}). The shape of funnel plots did not show any evidence of obvious asymmetry ([Figure 3](#f3-medscimonit-21-1408){ref-type="fig"}). Furthermore, the Egger's test result suggested that there was no significant publication bias (*P*=0.67).

Discussion
==========

This meta-analysis with a total of 3850 cases and 3947 controls systematically evaluated the association between BCHE K variant and AD risk. Results from this meta-analysis suggested that BCHE K variant was significantly associated with AD risk. In the subgroup analysis by ethnicity, a significant association between BCHE K variant and AD risk in Asians was found, but this result was not found in Caucasians. This difference suggests that race might play a role in AD. Only 5 studies were included in our meta-analysis; thus, more studies with Asians are needed to confirm our results. In the stratified analysis by *APOE* ɛ4 status, *APOE* ɛ4 carriers, but not *APOE* ɛ4 non-carriers with BCHE K variant, showed an increased AD risk. This result suggests that gene-gene interaction also plays an important role in the development of AD. More studies should be conducted to assess the interaction between other genes and BCHE K variant. When stratified by age at AD onset, we found that the risk of LOAD, but not EOAD, was significantly associated with BCHE K variant. This information indicates that age also has a critical role in AD development.

Carson et al. found that BCHE activity was associated with the amyloid and the neuritic component in neuritic plaques \[[@b33-medscimonit-21-1408]\]. Guillozet et al. also found that BCHE activity increased in the AD brain \[[@b34-medscimonit-21-1408]\]. The activity of serum BCHE-K to hydrolyze butyrylthiocholine was found to be reduced by 30% relative to BCHE-U \[[@b7-medscimonit-21-1408]\]. Thus, BCHE K variant might be associated with a decreased AD risk. However, Lopez et al. reported that BCHE K variant carriers were refractory to cholinesterase inhibitor therapy \[[@b35-medscimonit-21-1408]\]. Additionally, Podoly et al. found that BCHE K variant had an elevated AD risk due to inefficient interference with amyloidogenic processes \[[@b36-medscimonit-21-1408]\]. Furthermore, Ballard et al. found that BuCh E may play a role in the phosphorylation of tau, relevant to therapeutic inhibition of the enzyme \[[@b37-medscimonit-21-1408]\]. Alkalay et al. found no association between BChE activity and amyloid loads in the AD brain \[[@b38-medscimonit-21-1408]\]. Thus, the pathological role of BCHE K variant was still controversial. Our meta-analysis confirmed that this polymorphism might be associated with AD risk. More studies are needed to investigate the mechanism by which BCHE K variant could impact the risk of AD \[[@b39-medscimonit-21-1408],[@b40-medscimonit-21-1408]\].

This meta-analysis had several limitations. First, results of this meta-analysis were based on unadjusted OR, because not all studies offered the adjusted ORs. Second, although the number of included studies was relatively large, the sample size and statistical power was still limited. Third, we only included the published studies; thus, publication bias and selection bias might exist. Forth, lack of sufficient eligible data on BCHE K variant and AD limited our further stratified analyses.

Conclusions
===========

In conclusion, this study shows that BCHE K variant is associated with AD risk. More well-conducted studies with larger sample size are warranted to confirm our results.
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###### 

Characteristics of the case-control studies included in meta-analysis.

  First author    Year   Ethnicity   Age    Sex     Case (n)   Control (n)   BCHE K allele frequency (%)   APOE ɛ4 allele frequency (%)          
  --------------- ------ ----------- ------ ------- ---------- ------------- ----------------------------- ------------------------------ ------ ------
  Lehmann         1997   Caucasian   \>65   Mixed   74         104           13                            9                              41     16
  Brindle         1998   Caucasian   75.4   Mixed   138        165           20.3                          18.8                           31.4   14
  Crawford        1998   Caucasian   76.4   Mixed   391        201           17.2                          14.4                           75     67.4
  Hiltunen        1998   Caucasian   73     Mixed   59         59            12                            22                             100    100
  Kehoe           1998   Caucasian   NA     Mixed   181        262           21                            22                             56.5   28.1
  Singleton       1998   Caucasian   78.3   Mixed   119        83            20                            17                             65.5   21.4
  Yamada          1998   Asian       85.1   Mixed   48         107           31.7                          31.2                           NA     NA
  Grubber         1999   Caucasian   NA     Mixed   169        193           18.8                          23                             18     25.4
  Ki              1999   Asian       73     Mixed   78         74            23                            16                             28     7
  Tilley          1999   Caucasian   81     Mixed   177        118           20                            19                             31     11
  Wiebusch        1999   Caucasian   78     Mixed   135        70            25                            16                             43     18
  Yamamoto        1999   Asian       68.2   Mixed   149        200           15.9                          15.7                           NA     NA
  Lee             2000   Asian       69.1   Mixed   89         101           13.5                          12.3                           24.2   6.9
  Mattila         2000   Caucasian   \>65   Mixed   80         67            21                            15                             13     11
  McIlroy         2000   Caucasian   77.7   Mixed   175        187           26.8                          14.4                           34.5   31.6
  Kim             2001   Asian       71.7   Mixed   164        293           11.7                          10.1                           NA     NA
  Prince          2001   Caucasian   NA     Mixed   204        186           20.9                          20.1                           NA     NA
  Raygani         2004   Caucasian   75     Mixed   105        129           24.2                          12                             25.9   6.2
  Combarros       2005   Caucasian   75     Mixed   187        172           10                            15                             12     8
  Cook            2005   Caucasian   NA     Mixed   212        316           27                            20                             NA     NA
  Deniz-Naranjo   2007   Caucasian   \>60   Mixed   282        312           19.5                          19.4                           48.9   22.1
  Piccardi        2007   Caucasian   76.8   Mixed   158        118           21                            19                             18.9   5.5
  Mateo           2008   Caucasian   71.3   Mixed   231        221           12                            10                             NA     NA
  Bizzarro        2010   Caucasian   73.3   Mixed   167        129           10.1                          10.2                           NA     NA
  Simão-Silva     2013   Caucasian   74.5   Mixed   78         80            23                            21                             NA     NA

NA -- not available.

###### 

Results from this meta-analysis.

              OR (95% CI)[\*](#tfn3-medscimonit-21-1408){ref-type="table-fn"}   *P*    *I^2^* (%)
  ----------- ----------------------------------------------------------------- ------ ------------
  Overall     1.20 (1.03--1.39)                                                 0.02   0
  Asian       1.32 (1.02--1.72)                                                 0.04   0
  Caucasian   1.14 (0.95--1.37)                                                 0.16   0
  EOAD        1.16 (0.89--1.51)                                                 0.27   33
  LOAD        1.44 (1.05--1.97)                                                 0.02   15

EOAD -- early-onset Alzheimer's disease; LOAD -- late-onset Alzheimer's disease.

OR values refer to association between BCHE K variant and AD risk.

###### 

APOE ɛ4 and BCHE K variant interaction.

  APOE ɛ4   BCHE K   OR (95% CI)         *P*      *I^2^* (%)
  --------- -------- ------------------- -------- ------------
  −         −        Reference           --       --
  −         \+       1.11 (0.91--1.35)   0.30     45
  \+        −        2.81 (1.75--4.51)   0.0001   52
  \+        \+       3.31 (1.82--6.02)   0.0001   69
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